RxDoctor Payments Data

Ally Gordon, PA

Physician Assistant · Owings Mills, MDNPI 1487832663

Payments from drug & device makers

$5,697in general payments, 2019–2025

Across 182 payments — averaging $31.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Sumitomo Pharma America, Inc.$757
  • AbbVie$646
  • Astellas Pharma US Inc$615
  • Medtronic$560
  • Urovant Sciences Inc$411
  • plus $2K from 29 others

What the payments were for

  • Speaking & faculty fees$1122%
  • Travel & lodging$75213%
  • Food & beverage$4,45678%
  • Education$3777%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,697 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$175,459
Medicare patients
787
Services billed
3,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron262$183,336
MyrbetriqMirabegron185$106,313
PremarinEstrogens, Conjugated75$32,098
Mirabegron ErMirabegron17$5,348
Methenamine Hippurate65$5,210
Estradiol74$4,451
Solifenacin Succinate75$2,747
Fesoterodine Fumarate ErFesoterodine Fumarate23$2,172
Oxybutynin Chloride ErOxybutynin Chloride58$2,137
Tamsulosin Hcl128$2,074
NitrofurantoinNitrofurantoin Macrocrystal65$1,593
Desmopressin Acetate35$1,071
Dutasteride24$930
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$490
Finasteride29$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$757$183,336262 claims
Astellas Pharma US IncMyrbetriq$615$106,313185 claims
PfizerPremarin$28$32,09875 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →